PIII vs. LFMD, CORBF, SERA, AIRS, TOI, QIPT, EUDA, BDSX, XGN, and BGLC
Should you be buying P3 Health Partners stock or one of its competitors? The main competitors of P3 Health Partners include LifeMD (LFMD), Global Cord Blood (CORBF), Sera Prognostics (SERA), AirSculpt Technologies (AIRS), Oncology Institute (TOI), Quipt Home Medical (QIPT), EUDA Health (EUDA), Biodesix (BDSX), Exagen (XGN), and BioNexus Gene Lab (BGLC). These companies are all part of the "healthcare" industry.
P3 Health Partners vs.
P3 Health Partners (NASDAQ:PIII) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, community ranking, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.
P3 Health Partners has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, LifeMD has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500.
P3 Health Partners has a net margin of -6.95% compared to LifeMD's net margin of -12.06%. LifeMD's return on equity of 0.00% beat P3 Health Partners' return on equity.
LifeMD has lower revenue, but higher earnings than P3 Health Partners. LifeMD is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.
In the previous week, LifeMD had 1 more articles in the media than P3 Health Partners. MarketBeat recorded 2 mentions for LifeMD and 1 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.94 beat LifeMD's score of 0.89 indicating that P3 Health Partners is being referred to more favorably in the media.
LifeMD received 35 more outperform votes than P3 Health Partners when rated by MarketBeat users. Likewise, 76.47% of users gave LifeMD an outperform vote while only 26.67% of users gave P3 Health Partners an outperform vote.
P3 Health Partners presently has a consensus target price of $0.25, suggesting a potential upside of 52.35%. LifeMD has a consensus target price of $11.43, suggesting a potential upside of 129.49%. Given LifeMD's stronger consensus rating and higher probable upside, analysts plainly believe LifeMD is more favorable than P3 Health Partners.
7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 15.8% of P3 Health Partners shares are held by company insiders. Comparatively, 16.0% of LifeMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
LifeMD beats P3 Health Partners on 14 of the 19 factors compared between the two stocks.
Get P3 Health Partners News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIII and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
P3 Health Partners Competitors List
Related Companies and Tools
This page (NASDAQ:PIII) was last updated on 4/11/2025 by MarketBeat.com Staff
Buy PIII Stock Free PIII Stock Alerts